Imuski Injection contains Ranitidine at a concentration of 25 mg/ml, a histamine H2-receptor antagonist used primarily to reduce gastric acid secretion. It is indicated for the treatment and prevention of conditions associated with hyperacidity, such as peptic ulcer disease, gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and erosive esophagitis. Ranitidine works by competitively inhibiting H2 receptors on gastric parietal cells, thereby decreasing the volume and concentration of gastric acid produced. Imuski Injection is administered via intravenous or intramuscular routes, allowing for rapid onset of action, which is particularly beneficial in acute settings requiring prompt acid suppression. The dosage and duration of therapy should be individualized based on the clinical condition and patient response. Common adverse effects are generally mild and may include headache, dizziness, constipation, or diarrhea. Caution is advised in patients with renal or hepatic impairment, and dosage adjustments may be necessary. Imuski Injection should be used under medical supervision, with monitoring for potential drug interactions and contraindications, including hypersensitivity to ranitidine or other H2 antagonists. This formulation offers an effective option for managing acid-related gastrointestinal disorders in both inpatient and outpatient settings.